The role of 131I-MIBG in high-risk neuroblastoma treatment.
Despite aggressive research and treatment, high-risk neuroblastoma continues to have a devastating mortality rate of more than 40%. Research conducted over the past 2 decades has shown that the radioisotope (131)I-MIBG (metaiodobenzylguanidine) is effective in the treatment of this difficult patient population. The purpose of this article is to review the diagnosis, staging, and conventional treatment of neuroblastoma and to understand the mechanism of action of MIBG and ( 131)I-MIBG. This article also reviews treatments for high-risk neuroblastoma patients and analyzes recent research studies that used (131)I-MIBG to better define the role of this treatment in high-risk neuroblastoma patients. In addition, this article explores the role of the advanced practice nurse to serve at the forefront in the implementation of a multidisciplinary ( 131)I-MIBG treatment program.
Lessig
Megan Kinnear
MK
Division of Endocrinology at The Children's Hospital of Philadelphia, Philadelphia, PA, USA. lessigm@email.chop.edu
D019797:3-Iodobenzylguanidine / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D000071447:N-Myc Proto-Oncogene Protein; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D009687:Nuclear Proteins / Q000032:analysis; D015513:Oncogene Proteins / Q000032:analysis; D018570:Risk Assessment
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D019797:3-Iodobenzylguanidine